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Intrahepatic Dynamic Contrast-Enhanced
Magnetic Resonance Lymphangiography:
Potential Imaging Signature for Protein-
Losing Enteropathy in Congenital Heart
Disease
Bethan A. Lemley , MD; Dave M. Biko, MD; Aaron G. Dewitt, MD; Andrew C. Glatz , MD, MSCE;
David J. Goldberg, MD; Madhumitha Saravanan, BS; Michael L. O’Byrne, MD, MSCE;
Erin Pinto, MSN, RN, CCRN, FNP-BC; Chitra Ravishankar, MD; Jonathan J. Rome, MD;
Christopher L. Smith , MD, PhD; Yoav Dori, MD, PhD
BACKGROUND: Protein-losing enteropathy (PLE) is a significant cause of morbidity and mortality in congenital heart disease
patients with single ventricle physiology. Intrahepatic dynamic contrast-enhanced magnetic resonance lymphangiography
(IH-DCMRL) is a novel diagnostic technique that may be useful in characterizing pathologic abdominal lymphatic flow in the
congenital heart disease population and in diagnosing PLE. The objective of this study was to characterize differences in IH-
DCMRL findings in patients with single ventricle congenital heart disease with and without PLE.
METHODS AND RESULTS: This was a single-center retrospective study of IH-DCMRL findings and clinical data in 41 consecutive patients, 20 with PLE and 21 without PLE, with single ventricle physiology referred for lymphatic evaluation. There were
3 distinct duodenal imaging patterns by IH-DCMRL: (1) enhancement of the duodenal wall with leakage into the lumen, (2)
enhancement of the duodenal wall without leakage into the lumen, and (3) no duodenal involvement. Patients with PLE were
more likely to have duodenal involvement on IH-DCMRL than patients without PLE (P<0.001).
CONCLUSIONS: IH-DCMRL findings of lymphatic enhancement of the duodenal wall and leakage of lymph into the duodenal
lumen are associated with PLE. IH-DCMRL is a useful new modality for characterizing pathologic abdominal lymphatic flow in
PLE and might be useful as a risk-assessment tool for PLE in at-risk patients.
Key Words: magnetic resonance lymphangiography ■ protein-losing enteropathy ■ single ventricle heart defects ■
total cavopulmonary connection

P

rotein-losing enteropathy (PLE) is an uncommon
but worrisome complication arising in patients
with single ventricle heart defects. The condition
is characterized by disruption of the enteric mucosal
barrier and abnormal protein loss from the lymphatic
circulation via the bowel, resulting in perturbations
in multiple homeostatic systems. Classically in PLE,

hypoproteinemia results in decreased vascular oncotic
pressure leading to development of interstitial edema
and effusions.1 PLE may present with severe diarrhea,
malnourishment, and ascites/effusions, or more insidiously with subtle changes in bowel habits and trace
edema.1 A single-center study of a large cohort of patients post total cavopulmonary connection (TCPC, the
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CLINICAL PERSPECTIVE
What Is New?

• Protein-
losing enteropathy is associated with
significant morbidity and mortality in patients
with single ventricle congenital heart disease.
• The pathophysiology of protein-losing enteropathy is not well understood.
• Intrahepatic dynamic contrast-enhanced magnetic resonance lymphangiography shows that
patients with protein-
losing enteropathy often
have lymphatic perfusion of the duodenal wall
with spillage of lymph into the bowel lumen.

What Are the Clinical Implications?

• Intrahepatic dynamic contrast-enhanced magnetic resonance lymphangiography can guide
lymphatic intervention in patients with protein-
losing enteropathy.
• Intrahepatic dynamic contrast-
enhanced lymphangiography may have a role in assessing
the risk of protein-losing enteropathy in at-risk
patients.

Nonstandard Abbreviations and Acronyms
IH-DCMRL

IN-DCMRL

PLE
RV
SCPC
TCPC

intrahepatic dynamic contrast-
enhanced magnetic resonance
lymphangiography
intranodal dynamic contrast-
enhanced magnetic resonance
lymphangiography
protein-losing enteropathy
right ventricle
superior cavopulmonary connection
total cavopulmonary connection

Fontan operation) reported a freedom from PLE of 94%
at 10 years and 88% at 20 years,2 although given what
is known about the clinical spectrum of the presentation, it is possible that these are underestimates of the
true PLE prevalence in the single ventricle population.
While improvements in supportive care and treatment options have led to an improvement in the 5-
year survival from 46% to 88%, mortality associated
with PLE after TCPC remains high, and long-term
outcomes are poor.3,4 Although our understanding
of PLE has evolved, the residual morbidity and mortality burden likely reflects gaps in the current understanding of the pathophysiology of PLE. Current
evidence suggests that development of PLE is related to elevated central venous pressure that results

in lymphatic congestion due to both increased lymph
production and relative flow obstruction at the drainage point of the thoracic duct into the venous system. It is hypothesized that the congested lymphatic
system develops fistulous connections with the
bowel allowing for lymphatic decompression but resulting in protein loss and the development of clinical
PLE. However, not all patients with elevated central
venous pressure across their TCPC develop PLE,
suggesting there is more to the relationship between
PLE and the lymphatic system than has been thus
far elucidated.5
Historically there has been no role for lymphatic
imaging in evaluating PLE. Conventional lymphangiography is the primary modality for lymphatic intervention but has had limited diagnostic utility when it
comes to evaluating and understanding more global
lymphatic pathology. Conventional lymphangiography
is 2-dimensional. It provides no contextual information
regarding neighboring soft-
tissue structures and inadequate delineation of downstream lymphatic structures due to restricted distribution of water-
soluble
contrast.6 Dynamic contrast-enhanced magnetic resonance lymphangiography (DCMRL) was developed to
overcome these limitations. DCMRL is a 3-dimensional
imaging modality that offers excellent spatial and temporal resolution of the lymphatic system and surrounding structures.
We have previously reported on the role of DCMRL
in imaging the central lymphatic system.7 Intranodal
DCMRL (IN-DCMRL), in which MR lymphangiography
is performed after contrast agent is administered via
inguinal lymph node access, has become a routine
part of the diagnostic evaluation of patients with plastic
bronchitis or chylous pleural or pericardial effusions in
our center.8–10 In addition to delineating pathologic thoracic lymphatic flow patterns, IN-DCMRL has proven
useful in guiding lymphatic interventions.9,11 However,
the hepatic lymphatic network implicated in the pathophysiology of PLE is not well-visualized by IN-DCMRL
as hepatic lymphatics are upstream of the cisterna
chyli and do not enhance when contrast is administered via inguinal lymph node access.
Intrahepatic DCMRL (IH-DCMRL) in which contrast
agent is administered into peri-portal lymphatic channels, was developed to visualize hepatic lymphatic pathology with the goal of guiding intervention in PLE.6
In this study, we present findings of IH-DCMRL in patients with single ventricle physiology referred for lymphatic evaluation. Our primary aim was to compare the
IH-DCMRL findings of patients with PLE to those without PLE. Additionally, we characterized the differences
in imaging patterns in these patients and explored the
potential role of IH-DCMRL in the evaluation of patients
at risk for PLE.
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METHODS
Study Design and Population
This is a cross-sectional study with retrospective data
collection of consecutive patients with single ventricle
heart disease (shunt-
dependent or post-
superior or
total cavopulmonary connections) who underwent IH-
DCMRL as part of a standard, comprehensive, lymphatic evaluation at the Center for Lymphatic Disorders
at the Children’s Hospital of Philadelphia between
February 2018 and August 2019. Demographics, diagnoses, laboratory data, and echocardiographic and
catheterization parameters were extracted from the
electronic medical records. This study was approved
by The Children’s Hospital of Philadelphia Institutional
Review Board. Informed consent was waived. The
data that supports the findings of this study are available from the corresponding author upon reasonable
request.

Intrahepatic Dynamic Contrast-Enhanced
MR Lymphangiography
IH-
DCMRL studies were performed in a hybrid
catheterization-
magnetic resonance imaging laboratory. Lymphatic access was obtained in the cardiac
catheterization laboratory under general anesthesia
by a dedicated team of interventional cardiologists.
More detailed technique was described elsewhere
but briefly in all patients the hepatic lymphatic system
was accessed under ultrasound guidance using a 3.5
inch 25-guage spinal needle that was positioned near
a branch of the portal system and position was confirmed by fluoroscopy using a water-soluble contrast
agent.6 These patients also underwent intranodal lymphatic access. Access was secured with adhesives
and the patients were transferred to an adjacent MRI
suite.
MRIs were performed with a 1.5-
T magnet
(Siemens Healthineers MAGNETOM Avanto) using
undiluted gadobutrol (Gadavist, Bayer Healthcare)
at a dose of 0.1–0.2 mmol/kg injected by hand at
an approximate rate of 1–2 mL/min, as a contrast
agent.6 After injection of contrast, time-
resolved
imaging with interleaved stochastic trajectories
(TWIST) with temporal resolution of 8–12 seconds
was performed over 6–7 minutes and high-resolution
respiratory-
navigated 3D IR T1 gradient echo sequences over 2–5 minutes were performed as previously described.6
Imaging analysis was done by a team of pediatric
radiologists trained in lymphatic imaging. MRI reports
were reviewed for qualitative descriptions of abdominal
lymphatic findings. In the case of incomplete or unclear
reports, imaging was directly reviewed by a senior
member of the lymphatic disorders team (YD). Three
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categories of lymphatic imaging results were defined
as described below.

Statistical Analysis
PLE and other lymphatic diagnoses were extracted
from the intake letter generated at the time of each
subjects’ referral to the Center for Lymphatic Disorders
and were made by the patients’ treating cardiologists.
The method of PLE diagnosis was not independently
reviewed for the purposes of this study but all patients
in the PLE group had hypoalbuminemia. Patients in the
PLE cohort included subjects with and without other
concomitant lymphatic disorders. Descriptive statistics were calculated for the PLE and no-PLE cohorts
to demonstrate the comparability of the 2 cohorts.
Continuous variables were expressed as median (interquartile range). Categorical variables were expressed
as count (percent). Wilcoxon rank sum and Fisher’s
exact tests were used to evaluate the differences between the 2 cohorts. An alpha level of 0.05 was considered statistically significant.
The primary aim of the study was to evaluate the
differences in IH-DCMRL imaging patterns in the PLE
and no-PLE patients. A Fisher’s exact test was used to
evaluate the difference in distributions of patterns between the cohorts. A Fisher’s exact test was also used
in a sub-analysis of subjects who were post-TCPC. All
analyses were performed using STATA 16.1 (Statacorp,
College Station, TX).

RESULTS
Twenty patients with a diagnosis of PLE and 21 patients with no PLE diagnosis who were referred for
other lymphatic disorders, were included. Thirteen of
the patients had multiple lymphatic disorders, such as
plastic bronchitis and pleural effusions. Plastic bronchitis and pleural effusion were the most common
lymphatic diagnoses represented in the no-PLE cohort
(Table).
The PLE cohort was significantly older than the
no-PLE cohort, with a median age of 14.2 years compared to 5.3 years, respectively (P<0.001). The patients in the PLE cohort had all undergone TCPC. This
differed significantly from the distribution of surgical
stages in the no-PLE group (P=0.02). In the no-PLE
group, 15 patients were post TCPC, 4 patients were
post-superior cavopulmonary connection (SCPC), and
2 patients were pre-SCPC. The 2 groups had a similar
distribution of underlying cardiac diagnoses (P=0.14);
approximately a third of the patients in each group had
hypoplastic left heart syndrome.
The majority of patients in both groups had normal
or mildly diminished systolic function by echo, with no
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Demographics and Clinical Characteristics of PLE and no-PLE Cohorts
No PLE (N=21)

PLE (N=20)

Total (N=41)

P value

Age, y

5.3 (3.7–7.6)

14.2 (7.2–18.5)

7.6 (4.9–13.8)

<0.001

Height, cm

102.0 (90.0–112.0)

141.5 (121.5–162.0)

120.0 (101.0–142.0)

<0.001

Weight, kg

14.9 (11.0–21.7)

41.2 (23.4–53.6)

21.7 (14.8–41.9)

<0.001

Female

9 (42.9%)

8 (40.0%)

17 (41.5%)

>0.999

Systemic RV

14 (66.7%)

13 (65.0%)

27 (65.9%)

>0.999

Heterotaxy

7 (33.3%)

5 (25.0%)

12 (29.3%)

0.73

HLHS

7 (33.3%)

7 (35.0%)

14 (34.1%)

Other

3 (14.3%)

9 (45.0%)

12 (29.3%)

PA/IVS

1 ( 4.8%)

0 ( 0.0%)

1 ( 2.4%)

Tricuspid Atresia

4 (19.0%)

2 (10.0%)

6 (14.6%)

Unbalanced Canal

6 (28.6%)

2 (10.0%)

8 (19.5%)

pre-SCPC

2 ( 9.5%)

0 ( 0.0%)

2 ( 4.9%)

post-SCPC

4 (19.0%)

0 ( 0.0%)

4 ( 9.8%)

post-TCPC

15 (71.4%)

20 (100.0%)

35 (85.4%)

Albumin (prior to IH-DCMRL)

3.8 (3.4– 4.8)

3.0 (2.2–4.0)

3.5 (2.8–4.2)

0.002

Albumin (minimum)

3.0 (2.2–3.6)

2.3 (1.9–2.8)

2.5 (2.1–3.1)

0.03

Cardiac diagnosis

0.14

Surgical stage

0.02

Normal/mildly diminished function by echo

18 (85.7%)

17 (85.0%)

35 (85.4%)

>0.999

Enteral budesonide

1 ( 4.8%)

14 (70.0%)

15 (36.6%)

<0.001

Plastic bronchitis

11 (52.4%)

3 (15.0%)

14 (34.1%)

0.02

Pleural effusion

13 (61.9%)

5 (25.0%)

18 (43.9%)

Pericardial effusion

1 ( 4.8%)

0 ( 0.0%)

1 ( 2.4%)

>0.999

Ascites

1 ( 4.8%)

1 ( 5.0%)

2 ( 4.9%)

>0.999

No PLE (N=15)

PLE (N=20)

15.0 (13.0–16.0)

17.8 (13.5–19.3)

Lymphatic diagnoses

Central venous pressure (mm Hg)*

15.5 (13.5–18.0)

0.03

0.1

Continuous variables are expressed as median (interquartile range). Categorical variables are expressed as count (percentage). HLHS indicates hypoplastic
left heart syndrome; IH-DCMRL, intrahepatic dynamic contrast-enhanced magnetic resonance lymphangiography; PA/IVS, pulmonary atresia/intact ventricular
septum; PLE indicates protein-losing enteropathy; RV, right ventricle; SCPC, superior cavopulmonary connection; and TCPC, total cavopulmonary connection.
*Central venous pressure measurements included only patients who were post-total cavopulmonary connection.

significant difference between groups (P>0.999). In
patients post-
TCPC, there was no significant difference between the patients’ central venous pressures
measured at the time of IH-DCMRL between the PLE
and no-PLE cohorts (P=0.1).
As expected, the PLE patients had significantly
lower albumin levels than the patients with no PLE, with
a median albumin prior to IH-DCMRL of 3.0 g/dL and
3.8 g/dL (P=0.002), respectively, and a median minimum albumin of 2.3 g/dL and 3.0 g/dL, respectively
(P=0.03). More of the patients in the PLE cohort (70%)
were on enteral budesonide at the time of IH-DCMRL
than in the no-PLE group (P<0.001). Of those in the
PLE cohort not on enteral budesonide at the time of
IH-DCMRL, all but 1 patient had previously trialed enteral budesonide and reportedly discontinued it due to
inefficacy or intolerable side effects. One patient in the
no-PLE cohort was on enteral budesonide at the time

of IH-DCMRL. The patient had plastic bronchitis and
had no history of a PLE diagnosis.

Imaging Findings
IH-DCMRL was notable for 3 distinct lymphatic imaging
patterns with a spectrum of small bowel involvement:
(1) Contrast enhancement of the duodenal wall with
contrast leaking into the duodenal lumen, (2) contrast
enhancement of the duodenal wall without leakage into
the duodenal lumen, and (3) no contrast enhancement
of the duodenal wall or leakage into the lumen (Figure 1).
There was no enhancement of any other portions of the
small bowel wall by IH-DCMRL. Eighty-five percent of
the PLE cohort and 5% of the no-PLE cohort had enhancement of the duodenal wall with leakage into the
lumen. Fifteen percent of the PLE cohort and 10% of
the no-PLE cohort had enhancement of the duodenal
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Figure 1. Intrahepatic dynamic contrast-
enhanced magnetic resonance lymphangiography coronal sections in single
ventricle heart disease patients.
A, Duodenal wall enhancement and leakage of contrast into the bowel lumen (arrow) in a patient with PLE. Contrast distribution
subsequently visualized throughout bowel. B, Duodenal wall enhancement without leakage of contrast into the bowel lumen (arrow) in
a patient with PLE. C, No duodenal wall enhancement or leakage into the bowel lumen (arrow) in a patient without PLE. PLE indicates
protein-losing enteropathy.

wall without leakage into the lumen. And none of the
PLE cohort and 86% of the no-PLE cohort had no duodenal involvement. The difference in the distributions of
imaging patterns between the PLE and no-PLE cohorts
was statistically significant (P<0.001) (Figure 2A).
A sub-
analysis of the IH-
DCMRL findings restricted
to the patients who were post-TCPC was performed
(Figure 2B). When patients who had not undergone
TCPC were excluded, there remained 20 patients in
the PLE group and 16 patients in the no-PLE group.
A statistically significant difference between the distribution of imaging patterns in the PLE versus no-PLE
groups persisted (P<0.001).
Notably, 3 patients in the no-PLE cohort had duodenal involvement as seen by IH-DCMRL. Two of
these patients had duodenal wall enhancement without leakage into the lumen and one had duodenal wall
enhancement with leakage into the lumen. Of the patients without luminal leakage, one was a 3-year-old
with hypoplastic left heart syndrome post-TCPC with
chylous pleural effusions, and the other patient was
a 5-
year-
old with hypoplastic left heart syndrome
post TCPC with plastic bronchitis. Interestingly, the
5-
year-
old with plastic bronchitis was diagnosed
with PLE within 2 months of undergoing IH-DCMRL.
The 3-year-old with chylous pleural effusions had a
screening stool alpha-1-antitrypsin which was noted
retrospectively to be at the high range of normal. The
third patient without a PLE diagnosis who had duodenal involvement was a 5-month-old with hypoplastic

left heart and bidirectional Glenn, with chylous pleural
effusions. This patient’s imaging was challenging to interpret due to the patient’s small size, however, review
of the IH-DCMRL imaging was notable for duodenal
wall enhancement with a small amount of leakage
into the bowel lumen. Notably, all 3 of these patients
had low minimum albumin levels, ranging from 2.0 to
2.7 g/dL.
There were 3 patients with PLE who had duodenal
wall enhancement but no clear leakage of contrast into
the small bowel lumen by IH-DCMRL.

DISCUSSION
The pathophysiology of PLE is likely multifactorial
with inflammatory, physiologic, and anatomic factors
contributing to increased enteric protein loss and decreased vascular oncotic pressure.5,12–14 Therapeutic
approaches have generally targeted hypoproteinemia, the diminished integrity of intestinal mucosa,
and underlying altered hemodynamics.12 Treatment
options can also be classified as medical therapies
(diuretics, afterload reducers, inotropes, pulmonary
vasodilators, aldosterone antagonists, and steroids),
nutritional strategies (protein and triglyceride-
rich
diet and albumin infusions), and invasive catheter-
based interventions or surgical revisions.5,12 However,
none of these therapies have dramatically altered
the average PLE prognosis. A large multicenter
study of Fontan patients with PLE demonstrated
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A

B

Figure 2. Distributions of IH-DCMRL imaging patterns (duodenal wall enhancement with leakage
into the bowel lumen, duodenal wall enhancement with no leakage into the bowel lumen, and
no duodenal involvement) were significantly different between the PLE patients and the no-PLE
patients.
A, Patients at any surgical stage (P<0.001) (B) patients post TCPC (P<0.001). Bars are labeled with counts.
IH-DCMRL indicates intrahepatic dynamic contrast-enhanced magnetic resonance lymphangiography;
PLE, protein-losing enteropathy; and TCPC, total cavopulmonary connection.

that traditional treatment strategies have resulted in
symptomatic improvement in only modest proportions of patients and mortality remains high even
with treatment.5 Small series specifically evaluating
the utility of oral budesonide, a mainstay in treatment
of PLE, have demonstrated some improvement in
lab abnormalities but limited improvement in symptoms and outcome with significant steroid-
related
side effects.15–17 And evidence suggests that the
only truly effective treatment strategy for PLE is heart
transplant.18–22 The suboptimal response of Fontan
patients with PLE to common therapies strongly suggests that there are pathophysiologic mechanisms
underlying PLE that are not addressed by current
common treatment regimens.

There is growing evidence implicating lymphatic
system dysfunction in the development of PLE and
our results further support this hypothesis. Generally,
lymph from the hepatic lymphatic network flows to the
cisterna chyli, up the thoracic duct, and drains into
the systemic venous circulation (Figure 3A). We suspect in PLE there is a degree of abnormal retrograde
flow of lymph from the hepatic lymphatic network to
the duodenal wall. This can cause dilation of lacteals
in the duodenal wall and eventual rupture and leakage of lymph into the duodenal lumen (Figure 3B).
Previously intestinal lymphangiectasia has been described on pathology specimens from endoscopic
bowel biopsies in PLE patients.3,23 In 2 small series of
congenital heart disease patients with PLE, abnormal
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Figure 3. Diagram of the normal hepatic lymphatic networks showing flow from the liver towards the cisterna chyli and into
the thoracic duct (A) and hepatic lymphatic flow in PLE showing hepatoduodenal connections to the proximal duodenum (B).
Inset: Dilated lacteals in the duodenal wall are prone to rupture, spilling lymph into the bowel lumen. PLE indicates protein-losing
enteropathy.

retrograde hepatoduodenal lymphatic flow has been
demonstrated.24,25 In one of these studies, blue dye
injected into hepatic lymphatic networks could be
seen endoscopically, leaking from the wall of the duodenum into the duodenal lumen.24 Embolization of
hepatoduodenal lymphatic connections has resulted
in increased albumin levels and modest improvements
in PLE symptoms in some patients, supporting the hypothesis that hepatoduodenal connections contribute
to clinical PLE.24,25
In this study, patients with PLE universally had duodenal involvement as seen by IH-DCMRL. Instead
of draining to the cisterna chyli, some of the contrast injected into the hepatic lymphatic network
flowed retrograde causing duodenal wall enhancement. And in most cases of patients with PLE, there
was leakage of contrast into the duodenal lumen. In
contrast, most of the patients without PLE had no
enhancement of the duodenal wall or leakage into
the lumen on IH-DCMRL. Of the 3 patients without
a diagnosis of PLE who had duodenal involvement
on IH-DCMRL, one of these patients developed PLE
within months of imaging. Such patients may represent a cohort of patients at-risk for PLE or a cohort
with pre-symptomatic PLE who may soon progress
to clinical PLE. We do not universally collect stool
alpha-1 antitrypsin levels on all patients referred for
lymphatic evaluation, and therefore do not know if
these individuals would have met diagnostic criteria
for PLE at the time of IH-DCMRL.
IH-
DCMRL findings of duodenal wall enhancement and leakage of contrast into the duodenal lumen
represent a novel imaging signature for PLE with
important potential applications. At our institution

IH-DCMRL is performed in all patients referred for
lymphatic evaluation and results directly inform subsequent lymphatic interventions. In this study there
were no complications from the IH-DCMRL procedure. However, possible complications including
bleeding and infection could occur. In using a more
invasive procedure as a screening tool the risk and
benefit of the procedure needs to be considered and
should be studied.
In PLE patients, IH-DCMRL findings of duodenal
involvement typically lead to intervention, most often
embolization of hepatoduodenal lymphatic channels. Additionally, we propose that IH-DCMRL may
have a role in assessing for duodenal involvement in
populations at high-risk for PLE, such as those post-
TCPC with other lymphatic diagnoses. Duodenal
involvement observed in this population could alter
management. Just as T2-weighted MRI evaluation
of lymphatic anatomy pre-TCPC has proven useful
in predicting post-
operative clinical outcomes,26,27
IH-DCMRL could potentially be a useful modality for
pre-
operative risk-
assessment for developing PLE
post-TCPC.
In this study the PLE cohort was older and more
likely to have undergone TCPC than the no-PLE cohort. To evaluate whether duodenal involvement on
IH-
DCMRL was associated with PLE versus simply
post-TCPC status, a sub-analysis restricting to patients
post-TCPC was undertaken. In this analysis, there remained a statistically significant association between
duodenal involvement on IH-DCMRL and PLE diagnosis, making it unlikely that surgical stage alone was a
responsible for the association between PLE and findings of duodenal involvement by IH-DCMRL.
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